Summit Therapeutics Inc. Common Stock

Summit Therapeutics is trading at a $12.5B valuation with an RSI of just 34.7, deep in oversold territory, yet the absence of a P/E ratio signals the company remains unprofitable. This disconnect—a massive market cap for a pre-revenue or minimal-revenue biotech play—suggests the market is pricing in significant future catalysts rather than current fundamentals. The depressed RSI could indicate either a capitulation bottom or a warning that enthusiasm has fled ahead of clinical or regulatory setbacks. Without earnings visibility, this is purely a bet on pipeline execution, making sentiment swings particularly violent and the current technical weakness potentially deceptive rather than opportunistic.